Seroquel XR

See also: Generic Seroquel

Seroquel XR is a brand name of quetiapine, approved by the FDA in the following formulation(s):

SEROQUEL XR (quetiapine fumarate - tablet, extended release; oral)

• 
  Manufacturer: ASTRAZENECA
  
  Approval date: May 17, 2007
  
  Strength(s): EQ 200MG BASE ^[RLD], EQ 300MG BASE, EQ 400MG BASE, EQ 50MG BASE
  


• 
  Manufacturer: ASTRAZENECA
  
  Approval date: August 11, 2008
  
  Strength(s): EQ 150MG BASE
  

Has a generic version of Seroquel XR been approved?

No. There is currently no therapeutically equivalent version of Seroquel XR available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Seroquel XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Novel dibenzothiazepine antipsychotic
  Patent 4,879,288
  Issued: November 7, 1989
  Inventor(s): Warawa; Edward J. & Migler; Bernard M.
  Assignee(s): ICI Americas Inc.
  11-[4-[2-(2-Hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo[b,f][1,4 ]thiazepine is disclosed as a neuroleptic with a much reduced incidence of side effects such as acute dystonia and dyskinesia and tardive diskinesia.
  
  Patent expiration dates:
  
  
  • September 26, 2011
    
    ✓ 
    Patent use: TREATMENT OF SCHIZOPHRENIA
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 26, 2011
    
    ✓ 
    Patent use: TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 26, 2011
    
    ✓ 
    Patent use: TREATMENT OF BIPOLAR DISORDER
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • March 26, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical compositions using thiazepine
  Patent 5,948,437
  Issued: September 7, 1999
  Inventor(s): Parikh; Bhavnish Vinod & Timko; Robert Joseph & Addicks; William Joseph
  Assignee(s): Zeneca Limited
  The invention relates to sustained release formulations comprising 11-›4-›2-(2-hydroxyethoxy)ethyl!-1-piperazinyl!dibenzo›b,f! ›1,4!thiazepine or a pharmaceutically acceptable salt thereof, to methods of treating psychotic states and hyperactivity utilizing the sustained release formulations and to a process for preparing the sustained release formulations.
  
  Patent expiration dates:
  
  
  • May 28, 2017
    
    ✓ 
    Patent use: TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
    ✓ 
    Drug product
  
  
  
  • May 28, 2017
    
    ✓ 
    Patent use: TREATMENT OF SCHIZOPHRENIA
    ✓ 
    Drug product
  
  
  
  • May 28, 2017
    
    ✓ 
    Patent use: TREATMENT OF BIPOLAR DISORDER
    ✓ 
    Drug product
  
  
  
  • November 28, 2017
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 17, 2010 - PEDIATRIC EXCLUSIVITY
  
  
  • October 8, 2011 - MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA
  
  
  • October 8, 2011 - MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION
  
  
  • October 8, 2011 - ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA
  
  
  • October 8, 2011 - 50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER
  
  
  • April 8, 2012 - PEDIATRIC EXCLUSIVITY
  
  
  • December 2, 2012 - ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
  
  

See also...

• Seroquel XR Sustained-Release Tablets Consumer Information (Wolters Kluwer)
• Seroquel XR Consumer Information (Cerner Multum)
• Seroquel XR Advanced Consumer Information (Micromedex)
• Quetiapine Consumer Information (Wolters Kluwer)
• Quetiapine Sustained-Release Tablets Consumer Information (Wolters Kluwer)
• Quetiapine Consumer Information (Cerner Multum)
• Quetiapine Advanced Consumer Information (Micromedex)
• Quetiapine Fumarate AHFS DI Monographs (ASHP)